Company / Cash & Equivalents
Gain Therapeutics, Inc. Cash & Equivalents History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$10.4M
FY2024
5-year range
$7.3M / $36.9M
FY2021-FY2024
Trend
-11.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $7M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2024 with a 3-year CAGR of -34.5%.
Improved from $7M to $10M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -34.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -34.5%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 11.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $10.4M | -11.9% |
| FY2023 | $11.8M | +61.3% |
| FY2022 | $7.3M | -80.2% |
| FY2021 | $36.9M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026